Health Canada Notice on ICH Q3D (R1) the Guideline for Elemental ImpuritiesPublished on July 3, 2019
By: Pinky Mazumder
On May 31st, 2019, Health Canada issued a Notice titled the Release of the Finalised Guideline for ICH Q3D (R1): Guideline for Elemental Impurities and announced the implementation of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Q3D (R1) Guideline. The Guideline was developed by the ICH Expert Working Group and the final version was recommended for implementation by the members of ICH, including Health Canada. Health Canada endorses the principles and practices described in the Guideline.
The ICH Elemental Impurities guidance establishes Permitted Daily Exposures (PDEs) for 24 elemental impurities for oral, parenteral, and inhaled drug products. The factors considered in establishing the PDEs include:
-the oxidation state of the element in the drug product;
-human exposure and safety data;
-relevant animal study;
-route of administration; and,
The Guideline lists the PDEs for elements in Appendix 1 of the Guideline. In addition to the PDEs, the Guideline also mentions that when levels of elemental impurities are higher than the mentioned PDE, it can be justified in the following situations:
-short term dosing (i.e. less than 30 days); and,
Based on the likelihood of toxicity, the Guideline also classifies the elements into Class 1, Class 2, and Class 3 categories in order of decreasing toxicities. In March 2019, the Guideline was revised due to a revision in the PDE level for Cadmium. The potential sources of elemental impurities include residual impurities from the formulation or preparation of the drug product or its ingredients, elemental impurities that were introduced from the manufacturing equipment, and elemental impurities leached from the container closure systems.
The ICH Q3D (R1) Guideline applies to drug products including drug products containing purified proteins and polypeptides, however it does not apply to herbal products, vaccines, radiopharmaceuticals, among other drug products. Moreover, the Guideline on Elemental Impurities does not apply to drug products under clinical research. For detailed information on the Elemental Impurities Guideline, please refer to the Guideline cited in the Reference section below.
Thank you for reading Regulated Affairs, the CAPRA blog. CAPRA is a non-profit organization dedicated to providing professional development opportunities in Regulatory Affairs. Please feel free to share our blog posts and join us on social media.
ICH Q3D(R1): Guideline for Elemental Impurities
Rare Diseases and Orphan Drugs Regulatory Framework in Canada: Recent Initiatives by Government of Canada
What are Rare Diseases and How do They Affect Canadians? According to Health Canada, rare diseases are life-threatening, debilitating, or serious and chronic conditions that...
Health Canada changes filing requirements for product monographs
Did you know, effective immediately, Health Canada is changing the submission requirements for second language product monographs for human drugs? This is for only post-life...
Pragmatic Clinical Trials: Testing Treatments in the Real-World
What is a Pragmatic Clinical Trial? Clinical trials can be designed to be either pragmatic or explanatory. Explanatory trials are designed to find out whether a treatment...